Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector

Inclusion Criteria: * Primary hypercholesterolaemia (heterozygous familial or non-familial) or mixed dyslipidaemia AND confirmed vascular disease(\*) AND other regular risk factors(\*\*), OR confirmed familial heterozygous hypercholesterolaemia * Documented maximum dietary and drug lipid-lowering therapy within the last 12 months * Inadequate reduction of low-density lipoprotein cholesterol (LDL-C) despite maximum possible dietary and lipid-lowering therapy * The decision of the treating physician to use the PRALUENT® 2 ml SYDNEY auto-injector regardless of study enrolment * No previous therapy with a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor OR prior treatment with a PCSK9 inhibitor every 2 weeks (Q2W) or monthly (Q4W) * Signed Informed Consent Form (\*) Coronary heart disease (CHD), cerebrovascular manifestation, peripheral arterial occlusive disease (PAOD) (\*\*) For cardiovascular events (e.g. diabetes mellitus, renal function glomerular filtration rate (GFR) \< 60 ml/min) Exclusion Criteria: * Planned or existing pregnancy, cancer, drug or alcohol abuse, dementia, or general inability to understand the content of the observational study * Existing treatment by lipid apheresis * Age \< 18 years * Contraindications to treatment with alirocumab (PRALUENT®) according to the SmPC * Current participation in a clinical study The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.